Novel Engineered Plasmids And Optimized HEK293 Cell Line Improves AAV Productivity

Gene therapy developers face growing pressure to rapidly advance their AAV-based therapeutics into clinical trials. By harnessing Lonza's expertise and the same tools and technologies used in our platform process, you can achieve a balance between speed and risk while maintaining high AAV productivity. Lonza's Platform Process for AAV Manufacturing is built upon our proprietary suspension HEK293 cell line and plasmid vectors, proven to enhance AAV production. These essential materials are now accessible for your laboratory's use.